CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 31 enrolled
Drug / intervention
Blood and respiratory fluids sampling +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02853006
NCT02853006N/ACompleted
CompareCT.gov

Study on Fluids Associated to Lung Cancer, of the Ectopic Expression of Cancer Testis Gene and Mutation as Diagnostics and Prognosis Biomarkers

University Hospital, Grenoble·interventional·Posted Aug 2, 2016·Updated Mar 19, 2020

In Brief

A clinical study evaluating Blood and respiratory fluids sampling, Biopsy, and 1 other intervention for Lung Cancer. Completed, enrolled 31 participants across 1 site.

Detailed Summary

The diagnosis of lung cancer is the first cause of cancer deaths for man and woman. It requires invasive procedures (at least endoscopy, transthoracic puncture, or surgery). This study is about the set up of an innovative test for lung cancer prognosis, based on biopsies and surgical material : LungCancerTest, with the creation of a start-up in progress. The main goal of this study is to approve the diagnostic value of the molecular signature of the 26 genes (LungCancerTest) revealed in blood and respiratory fluids among patients with lung cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesFrance
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 2, 2016
Enrollment StartJun 1, 2015
Primary CompletionSep 1, 2019
Study CompletionFeb 1, 2020
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 9.9 years ago

Interventions

Blood and respiratory fluids samplingbiological

In order to extract RNA (LungCancerTest) and DNA (mutation, reassortment).

Biopsyprocedure

Excised tissuesprocedure